Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

PLoS Medicine
Arrigo F G CiceroLipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP)

Abstract

Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its average effect on plasma lipids in humans and its safety profile. We carried out a systematic review and meta-analysis of phase II and III randomized controlled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Scopus, Google Scholar, and Web of Science databases were searched, with no language restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids and high-sensitivity C-reactive protein (hsCRP) serum concentration were expressed as mean differences (MDs) and 95% confidence intervals (CIs). For safety analyses, odds ratios (ORs) and 95% CIs were calculated using the Mantel-Haenszel method. Bempedoic acid significantly reduced total cholesterol (MD -14.94%; 95% CI -17.31%, -12.57%; p < 0.001), non-high-density lipoprotein cholesterol (MD -18.17%; 95% CI -21.14%, -15.19%; p < 0.001), low-density lipoprotein cholesterol (MD -22.94%; 95% CI -26.63%, -19.25%; p < 0.001), low-density lipoprotein particle number (MD -20.67%; 95% CI -...Continue Reading

References

Jul 1, 1992·Journal of Clinical Epidemiology·D FollmannJ Cutler
Dec 1, 1956·Journal of Chronic Diseases·W HAENSZEL, N B HON
Dec 10, 2003·The Journal of Biological Chemistry·Anne P BeigneuxStephen G Young
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Aug 14, 2012·The Canadian Journal of Cardiology·Mark LemstraRyan Fung
Mar 13, 2013·Prevention Science : the Official Journal of the Society for Prevention Research·Michael Borenstein, Julian P T Higgins
Dec 11, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·W G MelsenM J M Bonten
Oct 4, 2014·Life Sciences·Maria Filomena de Jesus Raposo, Alcina Maria Miranda Bernardo de Morais
Feb 20, 2015·European Heart Journal·Erik S StroesUNKNOWN European Atherosclerosis Society Consensus Panel
Apr 16, 2015·The Journal of Cardiovascular Nursing·Martha Biddle, Lisa Kitko
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Jun 16, 2015·Journal of Clinical Lipidology·Paul D ThompsonRoger S Newton
May 4, 2016·The American Journal of Cardiology·Christie M BallantyneNarendra D Lalwani
Sep 27, 2016·Atherosclerosis·Anselm K GittBaishali Ambegaonkar
Nov 29, 2016·Nature Communications·Stephen L PinkoskyNarendra D Lalwani
Feb 6, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerMichael A Bush
Jun 14, 2017·Critical Reviews in Food Science and Nutrition·Amirhossein SahebkarArrigo F G Cicero
Jun 16, 2017·Expert Opinion on Biological Therapy·Giacomo PucciGiuseppe Schillaci
Apr 4, 2018·Cardiology Clinics·Anum Saeed, Christie M Ballantyne
Apr 16, 2018·Diabetes, Obesity & Metabolism·Federica FogacciArrigo Francesco Giuseppe Cicero
Sep 27, 2018·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Beth A Taylor, Paul D Thompson
Nov 28, 2018·The Cochrane Database of Systematic Reviews·Shipeng ZhanXiaojiao Wu
Mar 14, 2019·The New England Journal of Medicine·Kausik K RayUNKNOWN CLEAR Harmony Trial
Mar 30, 2019·Journal of the American Heart Association·Ulrich LaufsErik S G Stroes
May 7, 2019·Expert Opinion on Pharmacotherapy·Arrigo F G CiceroClaudio Borghi
May 18, 2019·Expert Opinion on Drug Discovery·Massimiliano RuscicaCesare R Sirtori
May 18, 2019·Expert Opinion on Drug Safety·Larysa StrilchukArrigo Fg Cicero
Sep 11, 2019·European Heart Journal·François MachUNKNOWN ESC Scientific Document Group

❮ Previous
Next ❯

Citations

Oct 20, 2020·Expert Review of Clinical Pharmacology·Georgios Polychronopoulos, Konstantinos Tziomalos
Jan 28, 2021·Cardiovascular Drugs and Therapy·Andrey V SusekovGerald F Watts
Aug 26, 2020·Journal of Cardiovascular Medicine·Furio ColivicchiDomenico Gabrielli
Jan 24, 2021·Atherosclerosis·Maciej Banach, Peter E Penson
Mar 12, 2021·Expert Review of Clinical Pharmacology·Huyen NguyenTianrui Yang
Apr 15, 2021·Deutsche medizinische Wochenschrift·Michael WagnerAli El-Armouche
May 1, 2021·International Journal of Molecular Sciences·Rosaria Vincenza GiglioManfredi Rizzo
May 27, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Uazman AlamHandrean Soran
Jun 19, 2021·Der Internist·Ursula KassnerElisabeth Steinhagen-Thiessen
Jul 2, 2021·Expert Opinion on Drug Metabolism & Toxicology·Arrigo F G CiceroIvan Cincione
Jun 17, 2021·Cardiology in Review·William SmithJames Nawarskas

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT03337308
NCT02659397
NCT02988115
NCT02666664
NCT03001076
NCT02072161
NCT01941836
NCT01607294
NCT01751984
NCT01262638

Software Mentioned

Cochrane
Scopus
Comprehensive Meta - Analysis ( CMA )
Google Scholar

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.